From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 1993
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 3.09
Pain Relevance 0.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (IL2RA) plasma membrane (IL2RA)
Anatomy Link Frequency
joint 2
IL2R 1
effector T-cells 1
IL2RA (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 8 100.00 Very High Very High Very High
Inflammation 4 97.96 Very High Very High Very High
Pain 6 97.28 Very High Very High Very High
Pain score 2 83.28 Quite High
cINOD 1 81.68 Quite High
tolerance 3 53.36 Quite High
cytokine 24 52.16 Quite High
corticosteroid 3 8.96 Low Low
pruritus 4 5.00 Very Low Very Low Very Low
Paracetamol 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 12 100.00 Very High Very High Very High
INFLAMMATION 4 100.00 Very High Very High Very High
Stress 2 98.52 Very High Very High Very High
Arthritis 1 98.20 Very High Very High Very High
Overactive Bladder 4 98.12 Very High Very High Very High
Pain 7 97.28 Very High Very High Very High
Disease 34 93.00 High High
Syndrome 12 89.24 High High
Mycosis Fungoides 12 89.12 High High
Ovarian Cancer 1 88.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Modulation of the IL2R was seen with doses of bexarotene 150 mg daily and higher.
Regulation (Modulation) of IL2R in IL2R
1) Confidence 0.25 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004568 Disease Relevance 0.53 Pain Relevance 0
Examination of the time courses of individual patients revealed significant positive correlations between changes in sIL2R levels and changes in swollen joint counts in five patients; significant correlations with other measures were present in three or fewer patients. sIL2R levels also varied little over the 2-week time interval of greatest clinical change in each patient.
Regulation (changes) of sIL2R in joint
2) Confidence 0.22 Published 1994 Journal Clin. Immunol. Immunopathol. Section Abstract Doc Link 7661913 Disease Relevance 0.30 Pain Relevance 0.12
The secondary endpoints were immunological – changes in CD4, CD8, CD25, CD69 and CD71.
Regulation (changes) of CD25
3) Confidence 0.15 Published 2006 Journal Retrovirology Section Body Doc Link PMC1590049 Disease Relevance 0.25 Pain Relevance 0.10
A potential drawback of both approaches is that activated, effector T-cells also transiently upregulate the expression of CD25 on their cell surface, therefore being at risk of depletion by strategies that target CD25.
Regulation (target) of CD25 in effector T-cells
4) Confidence 0.12 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2840411 Disease Relevance 0.82 Pain Relevance 0.05
OBJECTIVE: To examine synchronous changes in soluble interleukin-2 receptor (sIL-2R) levels, daily indicators of emotional stress, joint inflammation, and reported pain in patients with rheumatoid arthritis (RA).
Spec (examine) Regulation (changes) of soluble interleukin-2 receptor in joint associated with stress, pain, inflammation, rheumatoid arthritis and arthritis
5) Confidence 0.01 Published 1993 Journal Arthritis Rheum. Section Abstract Doc Link 8431208 Disease Relevance 0.71 Pain Relevance 0.23
The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8.
Regulation (effects) of soluble interleukin 2 receptor associated with inflammation and rheumatoid arthritis
6) Confidence 0.01 Published 1993 Journal J. Rheumatol. Section Title Doc Link 8308770 Disease Relevance 0.47 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools